rs876657970
Variant summary
Our verdict is Benign. Variant got -7 ACMG points: 0P and 7B. BP4_ModerateBP6BS2
The ENST00000369519.4(RBM20):āc.1013T>Cā(p.Met338Thr) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000165 in 1,398,132 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 13/18 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. M338V) has been classified as Uncertain significance.
Frequency
Consequence
ENST00000369519.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -7 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
RBM20 | NM_001134363.3 | c.1013T>C | p.Met338Thr | missense_variant | 2/14 | ENST00000369519.4 | NP_001127835.2 | |
RBM20 | XM_017016103.3 | c.848T>C | p.Met283Thr | missense_variant | 2/14 | XP_016871592.1 | ||
RBM20 | XM_017016104.3 | c.629T>C | p.Met210Thr | missense_variant | 2/14 | XP_016871593.1 | ||
RBM20 | XM_047425116.1 | c.629T>C | p.Met210Thr | missense_variant | 2/14 | XP_047281072.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
RBM20 | ENST00000369519.4 | c.1013T>C | p.Met338Thr | missense_variant | 2/14 | 1 | NM_001134363.3 | ENSP00000358532 | P1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD3 exomes AF: 0.0000129 AC: 2AN: 155224Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 82312
GnomAD4 exome AF: 0.0000165 AC: 23AN: 1398132Hom.: 0 Cov.: 32 AF XY: 0.0000160 AC XY: 11AN XY: 689342
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Primary dilated cardiomyopathy Uncertain:1Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Center for Advanced Laboratory Medicine, UC San Diego Health, University of California San Diego | May 14, 2019 | - - |
Uncertain significance, no assertion criteria provided | research | University of Washington Center for Mendelian Genomics, University of Washington | - | - - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Jun 22, 2015 | The p.Met338Thr variant in RBM20 has not been previously reported in individuals with cardiomyopathy and was absent from large population studies. Computational prediction tools and conservation analysis suggest that the p.Met338Thr variant may not impact the protein, though this information is not predictive enough to rule out pathogenicity. In summary, the clinical significance of the p.Met338Th r variant is uncertain. - |
Cardiovascular phenotype Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Oct 02, 2023 | The p.M338T variant (also known as c.1013T>C), located in coding exon 2 of the RBM20 gene, results from a T to C substitution at nucleotide position 1013. The methionine at codon 338 is replaced by threonine, an amino acid with similar properties. This variant co-occurred with a TTN A-band truncating variant and variants in other cardiac-related genes in two affected individuals from a family with dilated cardiomyopathy (Cowan JR et al. Circ Genom Precis Med, 2018 Jul;11:e002038). This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
Dilated cardiomyopathy 1DD Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 04, 2024 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at